These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 31069394)

  • 1. AlloDriver: a method for the identification and analysis of cancer driver targets.
    Song K; Li Q; Gao W; Lu S; Shen Q; Liu X; Wu Y; Wang B; Lin H; Chen G; Zhang J
    Nucleic Acids Res; 2019 Jul; 47(W1):W315-W321. PubMed ID: 31069394
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DeepAlloDriver: a deep learning-based strategy to predict cancer driver mutations.
    Song Q; Li M; Li Q; Lu X; Song K; Zhang Z; Wei J; Zhang L; Wei J; Ye Y; Zha J; Zhang Q; Gao Q; Long J; Liu X; Lu X; Zhang J
    Nucleic Acids Res; 2023 Jul; 51(W1):W129-W133. PubMed ID: 37078611
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular basis of drug resistance in smoothened receptor: An in silico study of protein resistivity and specificity.
    Sinha N; Chowdhury S; Sarkar RR
    Proteins; 2020 Mar; 88(3):514-526. PubMed ID: 31589795
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proteome-Scale Investigation of Protein Allosteric Regulation Perturbed by Somatic Mutations in 7,000 Cancer Genomes.
    Shen Q; Cheng F; Song H; Lu W; Zhao J; An X; Liu M; Chen G; Zhao Z; Zhang J
    Am J Hum Genet; 2017 Jan; 100(1):5-20. PubMed ID: 27939638
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Allosteric Methods and Their Applications: Facilitating the Discovery of Allosteric Drugs and the Investigation of Allosteric Mechanisms.
    Lu S; Shen Q; Zhang J
    Acc Chem Res; 2019 Feb; 52(2):492-500. PubMed ID: 30688063
    [TBL] [Abstract][Full Text] [Related]  

  • 6. OncoVar: an integrated database and analysis platform for oncogenic driver variants in cancers.
    Wang T; Ruan S; Zhao X; Shi X; Teng H; Zhong J; You M; Xia K; Sun Z; Mao F
    Nucleic Acids Res; 2021 Jan; 49(D1):D1289-D1301. PubMed ID: 33179738
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The mutational spectrum of squamous-cell carcinoma of the head and neck: targetable genetic events and clinical impact.
    Mountzios G; Rampias T; Psyrri A
    Ann Oncol; 2014 Oct; 25(10):1889-1900. PubMed ID: 24718888
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of peptide inhibitor as a therapeutic agent against head and neck squamous cell carcinoma (HNSCC) targeting p38alpha MAP kinase.
    Gill K; Singh AK; Kapoor V; Nigam L; Kumar R; Holla P; Das SN; Yadav S; Subbarao N; Mohanti BK; Dey S
    Biochim Biophys Acta; 2013 Mar; 1830(3):2763-9. PubMed ID: 23238519
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor derived mutations of protein tyrosine phosphatase receptor type k affect its function and alter sensitivity to chemotherapeutics in glioma.
    Agarwal S; Al-Keilani MS; Alqudah MA; Sibenaller ZA; Ryken TC; Assem M
    PLoS One; 2013; 8(5):e62852. PubMed ID: 23696788
    [TBL] [Abstract][Full Text] [Related]  

  • 10. AlloFinder: a strategy for allosteric modulator discovery and allosterome analyses.
    Huang M; Song K; Liu X; Lu S; Shen Q; Wang R; Gao J; Hong Y; Li Q; Ni D; Xu J; Chen G; Zhang J
    Nucleic Acids Res; 2018 Jul; 46(W1):W451-W458. PubMed ID: 29757429
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recurrent epigenetic silencing of the PTPRD tumor suppressor in laryngeal squamous cell carcinoma.
    Szaumkessel M; Wojciechowska S; Janiszewska J; Zemke N; Byzia E; Kiwerska K; Kostrzewska-Poczekaj M; Ustaszewski A; Jarmuz-Szymczak M; Grenman R; Wierzbicka M; Bartochowska A; Szyfter K; Giefing M
    Tumour Biol; 2017 Mar; 39(3):1010428317691427. PubMed ID: 28345455
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PTPRK suppresses progression and chemo-resistance of colon cancer cells via direct inhibition of pro-oncogenic CD133.
    Matsushita M; Mori Y; Uchiumi K; Ogata T; Nakamura M; Yoda H; Soda H; Takiguchi N; Nabeya Y; Shimozato O; Ozaki T
    FEBS Open Bio; 2019 May; 9(5):935-946. PubMed ID: 30947381
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting SHP2 Cryptic Allosteric Sites for Effective Cancer Therapy.
    Rehman AU; Zhao C; Wu Y; Zhu Q; Luo R
    Int J Mol Sci; 2024 Jun; 25(11):. PubMed ID: 38892388
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gene-expression signature regulated by the KEAP1-NRF2-CUL3 axis is associated with a poor prognosis in head and neck squamous cell cancer.
    Namani A; Matiur Rahaman M; Chen M; Tang X
    BMC Cancer; 2018 Jan; 18(1):46. PubMed ID: 29306329
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted next-generation sequencing identifies molecular subgroups in squamous cell carcinoma of the head and neck with distinct outcome after concurrent chemoradiation.
    Tinhofer I; Stenzinger A; Eder T; Konschak R; Niehr F; Endris V; Distel L; Hautmann MG; Mandic R; Stromberger C; Weichert W; Budach V
    Ann Oncol; 2016 Dec; 27(12):2262-2268. PubMed ID: 27681865
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutations of the LIM protein AJUBA mediate sensitivity of head and neck squamous cell carcinoma to treatment with cell-cycle inhibitors.
    Zhang M; Singh R; Peng S; Mazumdar T; Sambandam V; Shen L; Tong P; Li L; Kalu NN; Pickering CR; Frederick M; Myers JN; Wang J; Johnson FM
    Cancer Lett; 2017 Apr; 392():71-82. PubMed ID: 28126323
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma.
    Rebelatto MC; Midha A; Mistry A; Sabalos C; Schechter N; Li X; Jin X; Steele KE; Robbins PB; Blake-Haskins JA; Walker J
    Diagn Pathol; 2016 Oct; 11(1):95. PubMed ID: 27717372
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epidermal growth factor receptor (EGFR) and squamous cell carcinoma of the skin: molecular bases for EGFR-targeted therapy.
    Uribe P; Gonzalez S
    Pathol Res Pract; 2011 Jun; 207(6):337-42. PubMed ID: 21531084
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Illuminating biological pathways for drug targeting in head and neck squamous cell carcinoma.
    Choonoo G; Blucher AS; Higgins S; Boardman M; Jeng S; Zheng C; Jacobs J; Anderson A; Chamberlin S; Evans N; Vigoda M; Cordier B; Tyner JW; Kulesz-Martin M; McWeeney SK; Laderas T
    PLoS One; 2019; 14(10):e0223639. PubMed ID: 31596908
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rational design of cancer gene panels with OncoPaD.
    Rubio-Perez C; Deu-Pons J; Tamborero D; Lopez-Bigas N; Gonzalez-Perez A
    Genome Med; 2016 Oct; 8(1):98. PubMed ID: 27716338
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.